Next Article in Journal
Electrocardiographic Time-Intervals Waveforms as Potential Predictors for Severe Acute Kidney Injury in Critically Ill Patients
Next Article in Special Issue
Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
Previous Article in Journal
Fibula Nail versus Locking Plate Fixation—A Biomechanical Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 12
Issue 2
10.3390/jcm12020699
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)

by
Andrea Di Lenarda
1,*,
Gabriele Di Gesaro
2,
Filippo Maria Sarullo
3,
Daniela Miani
4,
Mauro Driussi
4,
Michele Correale
5,
Claudio Bilato
6,
Andrea Passantino
7,
Erberto Carluccio
8,
Alessandra Villani
9,
Luca degli Esposti
10,
Chiara d’Agostino
11,
Elena Peruzzi
12,
Simone Poli
13 and
Massimo Iacoviello
14,*
1
Cardiovascular Center, University Hospital and Health Services of Trieste, 34128 Trieste, Italy
2
U.O. Cardiologia IRCCS ISMETT, 90133 Palermo, Italy
3
U.O.S. Di Riabilitazione Cardiovascolare Ospedale Buccheri La Ferla Fatebenefratelli, 90123 Palermo, Italy
4
SOC Cardiologia, Dipartimento Cardiotoracico, Azienda Sanitaria Universitaria Friuli Centrale, Ospedale S. Maria della Misericordia, 33100 Udine, Italy
5
SC Universitaria di Cardiologia AOU “Ospedali Riuniti”, 71122 Foggia, Italy
6
U.O.C. Cardiologia Azienda ULSS 8 Berica—Ospedali dell’Ovest Vicentino, 36071 Arzignano, Italy
7
Division of Cardiology and Cardiac Rehabilitation, U.O. Cardiologia ICS Maugeri SpA SB Bari, IRCCS Istituto di Bari, 70124 Bari, Italy
8
Cardiologia e Fisiopatologia Cardiovascolare, Azienda Ospedaliera Universitaria “Santa Maria della Misericordia”, 06156 Perugia, Italy
9
U.O. Day Hospital—MAC Cardiologia, Istituto Auxologico Italiano—Ospedale S. Luca, 20149 Milan, Italy
10
CliCon S.r.l. Società Benefit, 40137 Bologna, Italy
11
Cardio-Metabolic Medical Manager, Novartis Farma SpA, 20154 Milan, Italy
12
Evidence Generation & Data Analytics Head, Novartis Farma SpA, 20154 Milan, Italy
13
RWE Data Analyst, Novartis Farma SpA, 20154 Milan, Italy
14
Surgical and Medical Sciences Department, University of Foggia, 71122 Foggia, Italy
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2023, 12(2), 699; https://doi.org/10.3390/jcm12020699
Submission received: 17 December 2022 / Revised: 7 January 2023 / Accepted: 10 January 2023 / Published: 16 January 2023
(This article belongs to the Special Issue Clinical Advances in Cardiomyopathies)
Browse Figures
Review Reports Versions Notes

Abstract

:
Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced ejection fraction (HFrEF). However, data of its routine real-world use are limited, and evidence from Italian settings is lacking. The REAL.IT study aimed to characterize the demographics, pharmacotherapy, clinical characteristics and outcomes of sacubitril/valsartan-treated Italian patients with HFrEF. Electronic medical records of patients initiating sacubitril/valsartan from October 2016 to June 2019 at nine specialized hospital outpatient HF centers across Italy were reviewed. Overall, 924 adults (mean age 64.5 years, 84.6% male) were included. At baseline, 38.7% had an ischemic HF etiology, 45.9% hypertension, 23.2% atrial fibrillation, 25.4% diabetes mellitus, 26.1% an implantable cardioverter-defibrillator and 31.9% coronary artery bypass grafting. There were no clear patterns of patient selection over time. During follow-up, NYHA class improved in 37.5% of patients after a mean of 5.3 ± 3.8 months; 36.1% and 16.7% of patients were in NYHA class III during characterization and after one year of follow-up, respectively. Left ventricular ejection fraction (LVEF) improved ≥5% in 56.3% of patients at one year; 39.7% had ≥30% reduction of N-terminal pro-B-type natriuretic peptide; 2.2% had hyperkalemia during characterization and 2.6% during follow-up; and 3.8% had hypotension during characterization and 12% during follow-up. A total of 50 (5.8%) of patients had device implantation (ICD/CRT) during follow-up. HF-related hospitalization was recorded in 19.6% of patients during follow-up; 3.8% of patients died, approximately 1.3% from cardiovascular causes. Our real-world data confirm the favorable effectiveness and tolerability of sacubitril/valsartan observed in pivotal randomized controlled trials.

1. Introduction

Over the last decades, the epidemiology of heart failure (HF) has been described as a global pandemic [1]. In Italy, HF prevalence has been estimated to be around 1.7% (i.e., in excess of 1 million people) and increases sharply with age [2,3]. Despite the progress of therapeutic approaches and the availability of comprehensive clinical practice guidelines, HF is still characterized by high morbidity and mortality [4,5]. Moreover, the underuse and underdosing of the recommended disease-modifying drugs has been shown to contribute to an even worse prognosis [6].
In this setting, real-world evidence reflecting the broader and unselected population encountered in routine clinical practice can describe patient characteristics and treatment patterns that differ from and complement those reported in randomized clinical trials which generally have more restrictive inclusion criteria. This evidence is even more relevant when analyzing the most recent drugs which have demonstrated their favorable effects, such as the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan. In fact, although sacubitril/valsartan has been established as a foundational treatment for HF based on clinical trial data, there remains a paucity of data from real-world settings about its use, the characteristics of patients treated in routine practice, their resource utilization and the effect on outcomes. Furthermore, evidence from clinical experience of sacubitril/valsartan in Italian settings is limited [7]. Therefore, observational studies using data from patients already treated with sacubitril/valsartan are needed to evaluate the use of this therapy in the real-world setting of everyday clinical practice in Italy, considering the indication criteria provided by the therapeutic plan.
To address this research gap, we undertook a multicenter, retrospective cohort study using data from Italian outpatient specialist clinics to describe the characteristics of patients treated with sacubitril/valsartan, including baseline demographics, pharmacotherapy, clinical characteristics, outcomes and resource and drug utilization. The principle focus of this paper is to describe the baseline demographic, clinical characteristics and clinical outcomes of Italian patients with HFrEF; an analysis of pharmacotherapy and resource and drug utilization will be reported later.

2. Patients and Methods

2.1. Study Design

This was an observational, retrospective, non-interventional cohort study based on electronic medical records from nine specialized hospital outpatient heart failure centers geographically distributed in the national territory of Italy. The principal investigators of REAL.IT.

2.2. Study Population

Consecutive ambulatory patients with a diagnosis of HF that attended the outpatient clinics for HF management and who had been prescribed sacubitril/valsartan from 1 October 2016 (the year of its launch in Italy) to 30 June 2019 (the inclusion period) were included in the study. The 30 June 2019 cut-off date allowed for a follow-up period of at least one year at the time of data extraction (30 June 2020). Specifically, all patients attending one of the outpatient clinics for the diagnosis and treatment of HF in the Italian centers involved who were ≥18 years old and had at least one prescription of sacubitril/valsartan from 1 October 2016 to 30 June 2019 were included in the study. The index date was defined as the date of the first prescription of sacubitril/valsartan during the inclusion period. A characterization period, i.e., the 6-month period before the index date, was used to assess the baseline characteristics of the overall patient population. The analyses comparing characterization and follow-up period were performed on patients with available information on the variables of interest during both periods. Patients with missing age or sex information were excluded from the analysis. The study design is shown in Figure 1.

2.3. Data Collection

Retrospective data were collected using the electronic medical records and the administrative databases of the centers, integrating patients’ personal health records, health examination records and hospital visit records. The study was conducted in compliance with the Declaration of Helsinki and current Italian regulations for observational studies. The ethics committee of each participating center was notified of the study, and the ethics committee of each participating center approved the study.

2.4. Variables

Patients were characterized using the following variables, with data collected no earlier than 6 months before the index date (i.e., the characterization period): demographic and previous clinical history, etiology of HF, presence of comorbidities, NYHA functional class, systolic blood pressure (SBP), hematochemical laboratory tests, including brain (B-type) natriuretic peptide (BNP) or N-terminal (NT)-proBNP (NT-proBNP), chronic kidney disease (CKD), electro- and echocardiographic data, cardiopulmonary exercise testing and pharmacological treatments for HF.
After 12 months of follow-up, the following variables were re-evaluated: clinical and functional parameters, including NYHA class, SBP, heart rate (HR), symptoms and signs of HF, routine hematochemical laboratory tests, standard electrocardiogram (ECG), and 2-dimensional (2-D) echocardiography to assess cardiac capacity and the effect of sacubitril/valsartan on cardiac function indices.
To assess the severity of HF, the following events were examined during follow-up: hospitalization related to HF, other CV events, non-CV causes, receipt of implantable cardioverter-defibrillator/coronary artery bypass grafting (PCI/CABG), valvular intervention, device implantation (ICD/cardiac resynchronization therapy [CRT]), number of emergency room visits and CV and non-CV mortality. As the study was based on the secondary use of data, safety monitoring and safety reporting were not a focus.

2.5. Objectives

The primary objective of the REAL.IT (real-world experience in HFrEF patients treated with sAc/vaL in Italy) study was to describe the characteristics of the patients treated with sacubitril/valsartan, including baseline demographics, pharmacotherapy and clinical characteristics in an Italian specialist setting overall and by calendar quarter (relating to time since launch).
A full listing of secondary and explorative objectives is provided in Supplementary Table S1. Objectives relevant to this paper are as follows: to evaluate, overall and by calendar quarter (relating to time since launch), the frequency of CV and non-CV death and the effect of treatment with sacubitril/valsartan on cardiac function indices.

2.6. Statistical Analysis

Continuous data were summarized in terms of the number of observations, the number of missing values, mean, and standard deviation (SD). Categorical data were summarized regarding the number of patients providing data, with frequency counts and percentages of patients in each category. Percentages were calculated using the number of observations with non-missing values as the denominator. The Chi-square test was used for categorical variables and the paired t-test was used to detect differences between the characterization and the follow-up periods for continuous variables (systolic and diastolic blood pressure, heart rate, and ejection fraction). Statistical significance was set at p < 0.05. All statistical analyses were performed using STATA SE, version 12.0 (StataCorp LLC, College Station, TX, USA). Data management was carried out using Microsoft SQL Server 2012.

3. Results

3.1. Patient Disposition

A total of 948 HF patients with at least one prescription of sacubitril/valsartan during all data availability periods were identified among the nine centers involved in the study. Of these, 924/948 adult HF patients were included in the analyses as they had at least one prescription of sacubitril/valsartan during the inclusion period, were without missing age or sex data and had 6 months of characterization period and at least 12 months of follow-up available. A flow chart of the study is shown in Figure 2.
Analyses comparing the characterization and follow-up periods were performed on patients with available information on the variables of interest during both periods. To maximize the value of the data within the database, further analyses were also carried out on all patients with available data for each variable considered.
Patient demographic and clinical characteristics are presented in Table 1. The mean age of patients was 64.5 ± 11.9 years and the majority of patients were in the age range 60–69 years (32.3%), followed by 70–79 years (27.2%) and 50–59 years (20.0%).
Seven-hundred and eighty-two (84.6%) patients were male, and 38.7% had an ischemic etiology of HF. A total of 45.9% of patients had hypertension, 25.4% diabetes mellitus, 31.9% PCI/CABG and 23.2% atrial fibrillation (Table 1).
Hypotension was recorded for 21 (3.8%) of patients during the characterization period, and 2.2% of patients had hyperkalemia. A total of 225 (26.1%) of patients had device implantation (ICD/CRT) during the characterization period.
When baseline data were stratified by calendar quarter, there were no clear patterns of selection of patients over time (Supplementary Table S2). Patients in each calendar quarter showed similar characteristics, and few differences were reported. Mean age in the three most recent quarters tended to be slightly older than in earlier quarters; the duration of HF disease tended to be slightly longer and symptoms more severe in the first quarters. However, there were no consistent trends in clinical and demographic characteristics over time.
A sub-analysis of baseline data in patients with 80% available data (N = 538) showed that 43.5% had hypertension, 35.3% had ischemic heart disease, 21.2% had diabetes mellitus and 28.3% PCI/CABG. In patients with 80% available data, 81.4% had a 2-D echocardiogram during the characterization period and 41.9% during follow-up.
As shown in Table 2, a significant reduction in the prescription of diuretics was observed during follow-up, whereas no differences were found in the prescription of mineralocorticoid receptor antagonists (MRAs) and beta-blockers.

3.2. Impact on NYHA Class

Baseline characteristics according to NYHA functional class showed that 63.8% were in NYHA class II during the characterization period and 66.4% during follow-up (Table 2). During the characterization period, 36.1% of patients were in NYHA class III. During follow-up, the proportion of patients in NYHA class III had reduced to 16.7%, and 16.2% (91 patients) were in class 1. NYHA class was unchanged in 57.4% of patients after a mean of 5.3 ± 3.8 months of follow-up and improved in 37.5%. NYHA class worsened in just 5.1% of patients after a mean of 6.3 ± 3.9 months follow-up (p < 0.001).

3.3. Impact on Ejection Fraction

Of the 316 patients with available data in both the characterization and follow-up periods, mean EF increased from 28.7% to 32.8% (p < 0.001) (Table 2). Of these patients, the percentage of patients with an improvement of left ventricular ejection fraction (LVEF) ≥5% was 56.3% (178/316 patients); 40 (12.7%) of patients had a worsening of LVEF of ≥5%, and 98 (31.0%) had LVEF values stable between ± 5% after a mean of 5.4 ± 4.1 months.

3.4. Hospitalizations and Events during Follow-Up

Among patients with available data (N = 744), 19.6% had at least one HF-related hospitalization during follow-up (Table 3). This represents 0.2 HF-related hospitalizations per patient during the one year of follow-up. Thirty-five (3.8%) patients died during follow-up, of which, according to the data availability, at least 12 were from CV causes.
Fifty patients (5.6%) of the 863 patients had device implantation during follow-up, without evidence during the characterization period.
Hypotension, the most common adverse event reported with sacubitril/valsartan in the PARADIGM-HF trial [8], was recorded for 66 patients (12.0%) during follow-up (Table 2).

3.5. Laboratory Data

Routine laboratory tests during characterization and follow-up periods are reported in Table 4. Of particular interest, mean values of NT-proBNP decreased by 20% during follow-up (from 1970 ng/L to 1580 ng/L, p < 0.001) among the 412 patients with available data. Specifically, 39.7% (164/413) and 27.3% (15/55) of patients had ≥30% reduction of NT-proBNP and BNP, respectively; 47.0% (194/413) and 36.4% (20/55) had stable values of NT-proBNP and BNP (±30%), respectively, while 13.3% (55/413) and 36.4% (20/55) had an increase of ≥30% of NT-proBNP and BNP values, respectively. A mild worsening of kidney function was reflected in a downward trend of around 5% in estimated glomerular filtration rate (eGFR) (Table 4). The proportion of patients with hyperkalemia was 2.6% during follow-up (Table 4).

4. Discussion

This present real-world, multicentric study provides a thorough characterization of patients who started therapy with sacubitril/valsartan in settings of routine clinical practice in Italy. The data from electronic medical records of HF patients referred to nine centers geographically distributed throughout the Italian national territory give insights into the baseline findings and changes in clinical characteristics during the first year of treatment with sacubitril/valsartan. Overall, a significant proportion of patients had improvements in EF, NYHA class, and levels of natriuretic peptides in the year after initiation of sacubitril/valsartan. Rates of HF-related hospitalization and death were low.
The demographic and clinical characteristics of the 924 patients included in the study were broadly in line with other international and real-world studies of patients treated with sacubitril/valsartan. When compared with the population of PARADIGM-HF, our population was characterized by a similar mean age of patients, (64.5 years in REAL.IT, compared with 63.8 years in the PARADIGM-HF) [8]. Further, the patients were younger than those of European and international real-world studies on sacubitril/valsartan utilization, whose ages ranged between 66 and 70 years [7,9,10,11,12]. Moreover, when compared with PARADIGM-HF, a lower percentage of patients were affected by diabetes (25.4% vs. 34.7%) and atrial fibrillation (23.2% vs. 36.2%). Interestingly, in our series a greater percentage of patients were taking diuretics and MRA when compared with PARADIGM-HF (87 vs. 80% and 77 vs. 56%). These differences are similar to those observed in other real-world studies [9]. It should be noted that patients in REAL.IT were referred to highly specialized centers for HF treatment and, therefore, may have been better controlled by cardiologists initiating sacubitril/valsartan therapy more promptly than may otherwise have occurred. The most frequent comorbidities encountered in the REAL.IT study were hypertension (45.9%) and ischemic heart disease (38.7%). Hypertension is also the most commonly reported comorbidity in real-world studies of sacubitril/valsartan [7,9,12], and the prevalence in our cohort falls in the middle of the reported range. Rates of both hypertension and ischemic heart disease etiology are lower in our study than in PARADIGM-HF [8], and may have been underestimated in REAL.IT perhaps partly because of the challenges of collecting real-world data. Moreover, the reported ischemic heart disease etiology of HF in sacubitril/valsartan real-world studies varies widely, ranging from 25% to 82% in systematic reviews [4,9].
NYHA stratification at baseline (64% NYHA II and 36% NYHA III) was consistent with other real-world data, which reports around 63% of patients with NYHA II and 30% with NYHA III [9]. Overall, a significant proportion of patients improved their clinical characteristics after starting therapy with sacubitril/valsartan. More than a third (37.5%) of patients moved to a less symptomatic NYHA class after around 5 months. One year after starting sacubitril/valsartan, the proportion of patients with NYHA III decreased from 36.1% to 16.7%, while the proportion of patients with NYHA I, absent during the characterization period, increased to 16.2%. Similar results were obtained in the Ariadne Registry, with almost 50% of patients improving from NYHA III to NYHA II and 16–18% from NYHA II to NYHA I [13]. This effect was also documented in the systematic review of nine studies by Proudfoot et al. [9] and by Haddad et al. [14].
In parallel, among patients with available data, 56.3% had an increased LVEF of ≥5% during follow-up, and 39.7% of patients had a ≥30% reduction in NT-proBNP levels after starting sacubitril/valsartan therapy. Elevated levels of natriuretic peptides are helpful in assessing prognosis in HF, and the statistically significant reduction in natriuretic peptides after starting sacubitril/valsartan is of particular relevance. Reductions in NT-proBNP concentrations were associated with sacubitril/valsartan-related benefits in the PARADIGM-HF study [8], and have been shown to be associated with reverse left ventricular remodeling during other guideline-directed medical therapies for HF [15,16]. The favorable effects of sacubitril/valsartan in reversing cardiac remodeling and improving systolic function as well as their relationship with NT-proBNP reduction have been also observed in a recent exploratory study at 12 months [17]. It was hypothesized that the reverse cardiac remodeling, established to be associated with improved prognosis in HF [18] as seen in our study, might offer a mechanistic explanation for the effects of sacubitril-valsartan in patients with HFrEF [17]. Other real-world studies have also examined levels of natriuretic peptides, showing consistent patterns of reduction in NT-proBNP in clinical practice [9,17]. In REAL.IT, the mean EF at baseline was 28.7%, which is within the range reported in the literature, between 23% and 38% [9]. Similarly to other published studies [19,20,21,22,23,24], there were indications of cardiac reverse remodeling in our patients following initiation of sacubitril/valsartan (LVEF increased ≥5% in 56.3%), and over 60% of patients had improvements in EF after a mean time of approximately 6 months. In PARADIGM-HF, sacubitril/valsartan was shown to be superior to enalapril in reducing hospitalizations for worsening HF, as well as CV-related and all-cause mortality in patients with ambulatory HFrEF [8]; additionally, and real-world comparative studies have consistently shown that sacubitril/valsartan reduces the rate of HF-related hospitalizations compared with standard of care [9]. In REAL.IT, 19.6% of patients had hospitalizations for HF in the year after sacubitril/valsartan initiation, a value within the range reported in other studies analyzing HF-related hospitalizations after the initiation of sacubitril/valsartan [7,9,13]. Accurate identification of the cause of death can be more problematic in a real-world setting than in more tightly controlled, randomized controlled trials; in REAL.IT, all-cause mortality during a year of follow-up was 3.8% (35 patients), although CV causes were confirmed for only approximately a third. Given the potential under-reporting of the outcomes analyzed, these data and the low proportion of deaths observed during the first year of follow-up could suggest effective management and a protective effect of sacubitril/valsartan in patients with HFrEF. Of interest, two studies that compared mortality in patients treated with sacubitril/valsartan or ACEi/ARB reported a rate of all-cause death of 6.8% at 6 months with sacubitril-valsartan versus 34.1% with ACEi/ARB [25], and 8.9% versus 12.2% (p < 0.05) [11].
Hypotension, as has been reported in other trials of sacubitril/valsartan, was the most common adverse event reported [8,26]. Patients who experienced a hypotensive episode, regardless of treatment assignment, were more likely to be on sub-target doses of ACEi or ARB before screening. Moreover, despite the higher incidence of symptomatic hypotension in sacubitril/valsartan-treated patients in PARADIGM-HF, the number of patients who had to discontinue the study drug was higher in the enalapril group, and sacubitril/valsartan recipients who developed hypotension also derived similar clinical benefits to those who did not experience hypotension, even if down-titrated to a lower dose of sacubitril/valsartan [27].
A mild worsening of kidney function was observed during follow-up, with a downward trend in the estimated eGFR for around 5%, which is consistent with the literature [7]. However, hyperkalemia was stable before and after starting therapy, with a minimal proportion of patients with hyperkalaemia on treatment. Of interest, concerns about the effects of ARNI on kidney function have been addressed in a recent cohort study of 27,166 patients, that found sacubitril/valsartan was not associated with higher rates of acute kidney injury than renin-angiotensin system inhibitors in patients newly intiating therapy [28]. Indeed, hyperkalemia and a decline of eGFR have been reported to be less likely to occur during treatment with sacubitril/valsartan than conventional ACEi therapy [29,30]. Additionally, as seen in this study, the use of sacubitril/valsartan may reduce the requirement for diuretics [25,31,32].
As this was a retrospective observational study analyzing anonymized data derived from electronic medical records, the study shares some limitations inherent in this type of study. For example, primary care data were not collected. Therefore, it was not possible to evaluate information about the role of primary care physicians in managing patients. In addition, the available data was incomplete for some patients, although this was accounted for in the analyses. Specifically, events can be underestimated if they are not meticulously registered in electronic records. Patients in the study were referred to the nine highly specialized HF centers, where they were managed by cardiologists that could have initiated the start of sacubitril/valsartan treatment more promptly than may otherwise have occurred. Therefore, they may not be fully representative of patients seen in routine general practice, and our findings may not be generalizable to the general population.

5. Conclusions

These real-world data on patients with HF treated with sacubitril/valsartan in settings of daily clinical practice in Italy confirm the effectiveness and tolerability observed within previous pivotal randomized clinical trials.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm12020699/s1, Table S1: Secondary and Exploratory Objectives of the REAL.IT Study; Table S2: Demographic and clinical characteristics at baseline for patients stratified by calendar quarter of inclusion.

Author Contributions

Conceptualization, A.D.L., G.D.G., F.M.S., D.M., M.D., M.C., C.B., A.P., E.C., A.V., L.d.E., C.d., E.P., S.P. and M.I.; methodology, A.D.L., G.D.G., F.M.S., D.M., M.D., M.C., C.B., A.P., E.C., A.V., L.d.E., C.d., E.P., S.P. and M.I.; software, L.d.E.; validation, L.d.E.; formal analysis, L.d.E.; investigation, A.D.L., G.D.G., F.M.S., M.D., M.C., C.B., E.C., A.V. and M.I.; resources, C.d., E.P and S.P.; data curation, A.D.L., G.D.G., F.M.S., D.M., M.D., M.C., C.B., A.P., E.C., A.V., L.d.E. and M.I.; writing—original draft, A.D.L., M.I.; writing—review & editing, G.D.G., F.M.S., D.M., M.D., M.C., C.B., A.P., E.C., A.V., L.d.E., C.d., E.P. and S.P.; supervision, C.d., E.P., S.P.; project administration, C.d., E.P. and S.P.; funding acquisition, C.d., E.P. and S.P. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. All authors have read and agreed to the published version of the manuscript.

Funding

CliCon S.r.l was funded by Novartis Farma SpA for this research, in order to collect, tom manage and analyze the anonymous patients’ data, which were sent by the participating centers.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and current Italian regulations for observational studies, and was notified to the Ethics Committee of each participating Center and every Ethic Committee of each participating Center approved the study.

Informed Consent Statement

Patient consent was waived as anonymized data were extracted from electronic medical records.

Data Availability Statement

Data are available from the corresponding author upon reasonable request.

Acknowledgments

We thank Ray Hill, an independent medical writer who provided medical writing support on behalf of Health Publishing & Services Srl. This support was funded by Novartis Farma SpA in accordance with Good Publication Practice.

Conflicts of Interest

Chiara d’Agostino, Elena Peruzzi, and Simone Poli are employees of Novartis Farma. The other authors declare no conflict of interest.

References

  1. GBD 2017 Disease Injury and Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Seferović, P.M.; Vardas, P.; Jankowska, E.A.; Maggioni, A.P.; Timmis, A.; Milinković, I.; Polovina, M.; Gale, C.P.; Lund, L.H.; Lopatin, Y. The Heart Failure Association Atlas: Heart failure epidemiology and management statistics 2019. Eur. J. Heart Fail. 2021, 23, 906–914. [Google Scholar] [CrossRef]
  3. Piccinni, C.; Antonazzo, I.C.; Simonetti, M.; Mennuni, M.G.; Parretti, D.; Cricelli, C.; Colombo, D.; Nica, M.; Cricelli, I.; Lapi, F. The burden of chronic heart failure in primary care in Italy. High Blood Press Cardiovasc. Prev. 2017, 24, 171–178. [Google Scholar] [CrossRef] [PubMed]
  4. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; Gonzalez-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016, 37, 2129–2200. [Google Scholar] [CrossRef] [Green Version]
  5. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Bohm, M.; Burri, H.; Butler, J.; Celutkiene, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726. [Google Scholar] [CrossRef]
  6. Savarese, G.; Bodegard, J.; Norhammar, A.; Sartipy, P.; Thuresson, M.; Cowie, M.R.; Fonarow, G.C.; Vaduganathan, M.; Coats, A.J.S. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: A multinational observational study (US, UK and Sweden). Eur. J. Heart Fail. 2021, 23, 1499–1511. [Google Scholar] [CrossRef] [PubMed]
  7. Giovinazzo, S.; Carmisciano, L.; Toma, M.; Benenati, S.; Tomasoni, D.; Sormani, M.P.; Porto, I.; Canepa, M.; Senni, M.; Metra, M.; et al. Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: A systematic review and meta-analysis. ESC Heart Fail. 2021, 8, 3547–3556. [Google Scholar] [CrossRef]
  8. McMurray, J.J.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014, 371, 993–1004. [Google Scholar] [CrossRef] [Green Version]
  9. Proudfoot, C.; Studer, R.; Rajput, T.; Jindal, R.; Agrawal, R.; Corda, S.; Senni, M. Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review. Int. J. Cardiol. 2021, 331, 164–171. [Google Scholar] [CrossRef]
  10. Zeymer, U.; Clark, A.L.; Barrios, V.; Damy, T.; Drozdz, J.; Fonseca, C.; Lund, L.H.; Kalus, S.; Ferber, P.C.; Hussain, R.I.; et al. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: Real-world data from the ARIADNE registry. Eur. Heart J. Qual. Care Clin. Outcomes 2022, 8, 469–477. [Google Scholar] [CrossRef]
  11. Polito, M.V.; Silverio, A.; Rispoli, A.; Vitulano, G.; Auria, F.; De Angelis, E.; Loria, F.; Gigantino, A.; Bonadies, D.; Citro, R.; et al. Clinical and echocardiographic benefit of sacubitril/valsartan in a real-world population with HF with reduced ejection fraction. Sci. Rep. 2020, 10, 6665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Houchen, E.; Loefroth, E.; Schlienger, R.; Proudfoot, C.; Corda, S.; Saha, S.; Satwase, S.K.; Studer, R. Hospitalization rates in patients with heart failure and reduced ejection fraction initiating sacubitril/valsartan or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: A retrospective cohort study. Cardiol. Ther. 2022, 11, 113–127. [Google Scholar] [CrossRef] [PubMed]
  13. Maggioni, A.P.; Clark, A.L.; Barrios, V.; Damy, T.; Drozdz, J.; Fonseca, C.; Lund, L.H.; Kalus, S.; Ferber, P.C.; Hussain, R.I.; et al. Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry. ESC Heart Fail. 2022, 9, 4209–4218. [Google Scholar] [CrossRef]
  14. Haddad, H.; Bergeron, S.; Ignaszewski, A.; Searles, G.; Rochdi, D.; Dhage, P.; Bastien, N. Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study. CJC Open 2020, 2, 344–353. [Google Scholar] [CrossRef] [PubMed]
  15. Daubert, M.A.; Adams, K.; Yow, E.; Barnhart, H.X.; Douglas, P.S.; Rimmer, S.; Norris, C.; Cooper, L.; Leifer, E.; Desvigne-Nickens, P.; et al. NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF. JACC Heart Fail. 2019, 7, 158–168. [Google Scholar] [CrossRef] [PubMed]
  16. Weiner, R.B.; Baggish, A.L.; Chen-Tournoux, A.; Marshall, J.E.; Gaggin, H.K.; Bhardwaj, A.; Mohammed, A.A.; Rehman, S.U.; Barajas, L.; Barajas, J.; et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: Mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur. J. Heart Fail. 2013, 15, 342–351. [Google Scholar] [CrossRef] [PubMed]
  17. Januzzi, J.L., Jr.; Prescott, M.F.; Butler, J.; Felker, G.M.; Maisel, A.S.; McCague, K.; Camacho, A.; Pina, I.L.; Rocha, R.A.; Shah, A.M.; et al. Association of change in N-terminal pro-B-Type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019, 322, 1085–1095. [Google Scholar] [CrossRef]
  18. Kramer, D.G.; Trikalinos, T.A.; Kent, D.M.; Antonopoulos, G.V.; Konstam, M.A.; Udelson, J.E. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach. J. Am. Coll. Cardiol. 2010, 56, 392–406. [Google Scholar] [CrossRef] [Green Version]
  19. Martens, P.; Beliën, H.; Dupont, M.; Vandervoort, P.; Mullens, W. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc 2018, 36, e12435. [Google Scholar] [CrossRef] [Green Version]
  20. Almufleh, A.; Marbach, J.; Chih, S.; Stadnick, E.; Davies, R.; Liu, P.; Mielniczuk, L. Ejection fraction improvement and reverse remodeling achieved with sacubitril/valsartan in heart failure with reduced ejection fraction patients. Am. J. Cardiovasc. Dis. 2017, 7, 108–113. [Google Scholar]
  21. Paolini, C.; Mugnai, G.; Dalla Valle, C.; Volpiana, A.; Ferraglia, A.; Frigo, A.C.; Bilato, C. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up. Int. J. Cardiol. Heart Vasc. 2021, 35, 100821. [Google Scholar] [CrossRef] [PubMed]
  22. Moon, M.G.; Hwang, I.C.; Choi, W.; Cho, G.Y.; Yoon, Y.E.; Park, J.B.; Lee, S.P.; Kim, H.K.; Kim, Y.J. Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction. ESC Heart Fail. 2021, 8, 2058–2069. [Google Scholar] [CrossRef] [PubMed]
  23. Oh, J.H.; Lee, J.M.; Lee, H.J.; Hwang, J.; Lee, C.H.; Cho, Y.K.; Park, H.S.; Yoon, H.J.; Chung, J.W.; Kim, H.; et al. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients. ESC Heart Fail. 2022, 9, 2435–2444. [Google Scholar] [CrossRef] [PubMed]
  24. Pastore, M.C.; Mandoli, G.E.; Giannoni, A.; Benfari, G.; Dini, F.L.; Pugliese, N.R.; Taddei, C.; Correale, M.; Brunetti, N.D.; Carluccio, E.; et al. Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: Insights from DISCOVER-ARNI, a multicenter Italian register. Eur. Heart J. Open 2022, 2, oeab046. [Google Scholar] [CrossRef]
  25. De Vecchis, R.; Ariano, C.; Di Biase, G.; Noutsias, M. Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction: A retrospective cohort study. Herz 2019, 44, 425–432. [Google Scholar] [CrossRef]
  26. Zhang, H.; Huang, T.; Shen, W.; Xu, X.; Yang, P.; Zhu, D.; Fang, H.; Wan, H.; Wu, T.; Wu, Y.; et al. Efficacy and safety of sacubitril-valsartan in heart failure: A meta-analysis of randomized controlled trials. ESC Heart Fail. 2020, 7, 3841–3850. [Google Scholar] [CrossRef]
  27. Vardeny, O.; Claggett, B.; Kachadourian, J.; Pearson, S.M.; Desai, A.S.; Packer, M.; Rouleau, J.; Zile, M.R.; Swedberg, K.; Lefkowitz, M.; et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor with Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ. Heart Fail. 2018, 11, e004745. [Google Scholar] [CrossRef]
  28. Bhatt, A.S.; Vaduganathan, M.; Zhuo, M.; Fu, E.L.; Solomon, S.D.; Desai, R.J. Risk of acute kidney injury among older adults with heart failure with reduced ejection fraction treated with angiotensin-neprilysin inhibitor versus renin-angiotensin system inhibitor in routine clinical care. J. Card. Fail. 2022, in press. [Google Scholar] [CrossRef]
  29. Damman, K.; Gori, M.; Claggett, B.; Jhund, P.S.; Senni, M.; Lefkowitz, M.P.; Prescott, M.F.; Shi, V.C.; Rouleau, J.L.; Swedberg, K.; et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018, 6, 489–498. [Google Scholar] [CrossRef]
  30. Desai, A.S.; Vardeny, O.; Claggett, B.; McMurray, J.J.; Packer, M.; Swedberg, K.; Rouleau, J.L.; Zile, M.R.; Lefkowitz, M.; Shi, V.; et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: A secondary analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017, 2, 79–85. [Google Scholar] [CrossRef]
  31. Vardeny, O.; Claggett, B.; Kachadourian, J.; Desai, A.S.; Packer, M.; Rouleau, J.; Zile, M.R.; Swedberg, K.; Lefkowitz, M.; Shi, V.; et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: The PARADIGM-HF trial. Eur. J. Heart Fail. 2019, 21, 337–341. [Google Scholar] [CrossRef] [PubMed]
  32. Carluccio, E.; Dini, F.L.; Bitto, R.; Ciccarelli, M.; Correale, M.; D’Agostino, A.; Dattilo, G.; Ferretti, M.; Grelli, A.; Guida, S.; et al. Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. Int. J. Cardiol. 2022, 350, 62–68. [Google Scholar] [CrossRef] [PubMed]
Jcm 12 00699 g001 550
Figure 1. Study design. The study period was between 1 April 2016 and 30 June 2020, and the inclusion period was between 1 October 2016 and 30 June 2019. There was a characterization period of 6 months before the index date (the date of the first prescription of sacubitril/valsartan), and all patients were followed up for at least 12 months from the index date to June 2020.
Figure 1. Study design. The study period was between 1 April 2016 and 30 June 2020, and the inclusion period was between 1 October 2016 and 30 June 2019. There was a characterization period of 6 months before the index date (the date of the first prescription of sacubitril/valsartan), and all patients were followed up for at least 12 months from the index date to June 2020.
Jcm 12 00699 g001
Jcm 12 00699 g002 550
Figure 2. Flow chart of the study. * Patients with missing age or sex data and/or who did not have 6 months of characterization period and at least 12 months of follow-up available were excluded.
Figure 2. Flow chart of the study. * Patients with missing age or sex data and/or who did not have 6 months of characterization period and at least 12 months of follow-up available were excluded.
Jcm 12 00699 g002
Table
Table 1. Baseline demographic and clinical characteristics of patients treated with sacubitril/valsartan during the characterization period *.
Table 1. Baseline demographic and clinical characteristics of patients treated with sacubitril/valsartan during the characterization period *.
Characteristic
N = 924
Age, (years) mean ± SD64.5 ± 11.9
Gender, n (%)
          Male782/924 (84.6)
          Female142/924 (15.4)
Ischemic heart disease, n (%)232/599 (38.7)
PCI/CABG, n (%)191/599 (31.9)
Moderate or severe mitral or aortic valvular disease, n (%)99/599 (16.5)
Implanted prosthetic valve, n (%)33/229 (14.4)
Devices (ICD/CRT), n (%)225/863 (26.1)
Atrial fibrillation, n (%)214/924 (23.2)
Prior hospitalization for HF, n (%)194/538 (36.1)
Previous stroke, n (%)17/460 (3.7)
Diabetes mellitus, n (%)235/924 (25.4)
Hypertension, n (%)424/924 (45.9)
Chronic kidney disease, n (%)142/597 (23.8)
CKD §, n (%)304/829 (36.7)
Duration of HF disease ** (years), mean ± SD6.8 ± 6.0
* Data are shown for patients with available data during the characterization period, which was defined as the 6-month period before the index date, the date of first prescription of sacubitril/valsartan during the inclusion period. Patients were followed up for at least 12 months. ** N = 580 patients with available data. § considering patients with available data for diagnosis of CDK and those for whom CDK was deduced from creatinine value considering the eGFR. Abbreviations: CABG = coronary artery bypass grafting; CKD = chronic kidney disease; CRT = cardiac resynchronization therapy; HF = heart failure; ICD = implantable cardioverter defibrillator; PCI = percutaneous coronary intervention; SD = standard deviation.
Table
Table 2. Clinical examinations in patients with available data during characterization and follow-up periods *.
Table 2. Clinical examinations in patients with available data during characterization and follow-up periods *.
CharacteristicPatients, nCharacterization PeriodFollow-Up Periodp Value
NYHA Class, n (%)
I563NI a91 (16.2)<0.001
II563359 (63.8)374 (66.4)
III563203 (36.1)94 (16.7)
IV563–4 (0.7)
Blood pressure, mmHg, mean ± SD
SBP551121 ± 16114 (17)<0.001
DBP55173 ± 1068 (10)<0.001
Hypotension **, n (%)55121 (3.8)66 (12.0)<0.001
Heart rate, BPM, mean ± SD45569 ± 1167 ± 10<0.001
Electrocardiogram, n (%)727570 (78.4)417 (57.4)<0.001
2-D Echocardiogram, n (%)924752 (81.4)387 (41.9)<0.001
Ejection fraction, %, mean ± SD31628.7 ± 5.832.8 ± 7.9<0.001
Drug therapy
ACE-i, n (%)686462 (67.3)27 (3.9)<0.001
ARBs, n (%)686185 (27.0)20 (2.9)<0.001
Beta-blockers, n (%)553533 (96.4)531 (96.0)0.753
MRA, n (%)553425 (76.9)425 (76.9)1
Diuretics, n (%)686599 (87.3)566 (82.5)0.013
Ivabradine, n (%)68651 (7.4)58 (8.5)0.485
Digitalis, n (%)68636 (5.2)41 (6.0)0.558
* The characterization period was defined as the 6-month period before the index date, the date of the first prescription of sacubitril/valsartan during the inclusion period. Patients were followed up for at least 12 months. ** Hypotension was defined as SBP < 95 mmHg. a Data available for only ≤3 patients were not included (NI) in the analysis. Abbreviations: 2-D = 2-dimensional; ACE-i: angiotensin-converting enzyme inhibitor; ARBs: angiotensin II receptor blockers; BPM = beats per minute; DBP = diastolic blood pressure; MRA: mineralocorticoid receptor antagonists; NYHA = New York Heart Association; SBP = systolic blood pressure; SD = standard deviation.
Table
Table 3. Cardiovascular and unrelated events during follow-up *.
Table 3. Cardiovascular and unrelated events during follow-up *.
ParameterPatients with Available Data, nFollow-Up Period
Hospitalization
HF-related, n (%)744146 (19.6)
          Per patient during the 1-year period of follow-up, mean ± SD7440.2 ± 0.5
Other CV events, n (%)579118 (20.4)
          Per patient during the 1-year period of follow-up, mean ± SD5790.2 ± 0.4
Non-CV causes, n (%)46189 (19.3)
          Per patient during the 1-year period of follow-up, mean ± SD4610.2 ± 0.5
Device implantation (ICD/CRT), n (%)86350 (5.8)
HF-related emergency room visits, n (%)33366 (19.8)
Death **, n (%)92435 (3.8)
* Patients were followed up for at least 12 months. ** 16 patients had the information regarding the CV-related cause of death. CRT = cardiac resynchronization therapy; CV = cardiovascular; HF = heart failure; ICD = implantable cardioverter-defibrillator; SD = standard deviation.
Table
Table 4. Routine laboratory test results in patients with available data during characterization and follow-up periods *.
Table 4. Routine laboratory test results in patients with available data during characterization and follow-up periods *.
CharacteristicPatients with Available Data, nCharacterization PeriodFollow-Up Periodp Value
Hemoglobin (g/dL), mean ± SD34713.6 ± 1.613.5 ± 2.00.480
Glycated hemoglobin (mmol/mol), mean ± SD8750 ± 1449 ± 150.445
Creatinine (mg/dL), mean ± SD5511.20 ± 0.351.28 ± 0.48<0.001
Estimated glomerular filtration rate **, mean ± SD55168.06 ± 22.5164.97 ± 22.94<0.001
          45.00 ≤ eGFR < 60.00), n (%)551114 (20.7)126 (22.9)<0.001
          30.00 ≤ eGFR < 45.00), n (%)55187 (15.8)96 (17.4)<0.001
          15.00 ≤ eGFR < 30.00), n (%)5518 (1.5)22 (4.0)<0.001
          eGFR < 15.00), n (%)551–NI a<0.001
Sodium (mmol/L), mean ± SD503140 ± 5141 ± 30.008
Potassium (mmol/L), mean ± SD5074.65 ± 6.134.43 ± 0.500.427
Hyperkalemia †, n (%)50711 (2.2)13 (2.6)0.679
B-type natriuretic peptide (ng/L), mean ± SD55424 ± 354504 ± 7830.491
NT-proBNP (ng/L), mean ± SD4131970 ± 26501580 ± 2633<0.001
Uric acid (mg/dL), mean ± SD516.16 ± 1.866.04 ± 1.790.565
* The characterization period was defined as the 6-month period before the index date, the date of the first prescription of sacubitril/valsartan during the inclusion period. Patients were followed up for at least 12 months. ** calculated by the CKD-EPI method. † Defined as K > 5.4 mmol/L. a Data available for ≤3 patients only were not included (NI) in the analysis. Abbreviations: BNP = B-type natriuretic peptide; eGFR = estimated glomerular filtration rate; NT = N-terminal; SD = standard deviation.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Di Lenarda, A.; Di Gesaro, G.; Sarullo, F.M.; Miani, D.; Driussi, M.; Correale, M.; Bilato, C.; Passantino, A.; Carluccio, E.; Villani, A.; et al. Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study). J. Clin. Med. 2023, 12, 699. https://doi.org/10.3390/jcm12020699

AMA Style

Di Lenarda A, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M, Bilato C, Passantino A, Carluccio E, Villani A, et al. Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study). Journal of Clinical Medicine. 2023; 12(2):699. https://doi.org/10.3390/jcm12020699

Chicago/Turabian Style

Di Lenarda, Andrea, Gabriele Di Gesaro, Filippo Maria Sarullo, Daniela Miani, Mauro Driussi, Michele Correale, Claudio Bilato, Andrea Passantino, Erberto Carluccio, Alessandra Villani, and et al. 2023. "Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)" Journal of Clinical Medicine 12, no. 2: 699. https://doi.org/10.3390/jcm12020699

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop